- A new discovery may lead to a treatment for improving lung function in smokers.
- A common antibiotic has been found to reduce acute symptoms of chronic obstructive pulmonary disease
- According to Australian researchers, cigarette smoke exposure permanently alters the cellular structure of the tissues in the airway from people with Chronic Obstructive Pulmonary Disease (COPD). Causing airway thickening and even causing precancerous cells to increase long after cigarette smoke exposures has ended.
- Patients with rheumatoid arthritis are two times more likely to have concurrent chronic obstructive pulmonary disease (COPD) than healthy controls -- an association which was sustained even when variables such as age, gender, smoking and obesity were controlled for, according to a study presented today at the EULAR 2011 Annual Congress.
- The six-minute walking distance test (6MWD), a test that measures a patient's ability to tolerate exercise and physical activity, is an effective tool for understanding disease severity in patients with chronic obstructive pulmonary disease (COPD), according to a three-year global study of patients with COPD sponsored by drug manufacturer GlaxoSmithKline.
- Michael Croft, Ph.D., a researcher at the La Jolla Institute for Allergy & Immunology, has discovered a molecule's previously unknown role as a major trigger for airway remodeling, which impairs lung function, making the molecule a promising therapeutic target for chronic asthma, chronic obstructive pulmonary disease (COPD) and several other lung conditions. A scientific paper on Dr. Croft's finding was published online today in the prestigious journal, Nature Medicine.
- The U.S. Food and Drug Administration approved roflumilast, a pill taken daily to decrease the frequency of flare-ups (exacerbations) or worsening of symptoms from severe chronic obstructive pulmonary disease (COPD).
- Researchers have proved that a single "master switch" enzyme, known as aldose reductase, is key in producing excess mucous that clogs the airways of people with asthma and chronic obstructive pulmonary disease (COPD).
- Patients suffering from chronic obstructive pulmonary disease (COPD) who are on long-term oxygen therapy (LTOT) have more to worry about than breathing difficulties. According to a new study by researchers in Sweden, COPD patients on LTOT today face an increased risk of death from cardiovascular disease and other non-respiratory ailments.
- Researchers from Duke University Medical Center have identified how nanoparticles from diesel exhaust damage lung airway cells, a finding that could lead to new therapies for people susceptible to airway disease.
- Moderate to severe chronic obstructive pulmonary disease (COPD) may be an auto-immunity problem, according to researchers in Spain, who studied the presence of auto-antibodies in patients with COPD and compared them to levels of control subjects.
- The number of Americans who report being aware of chronic obstructive pulmonary disease, or COPD, increased by 4 percentage points between 2008 and 2010, but many people at risk are still unaware of the disease, according to mailed survey results released today by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.
Chronic obstructive pulmonary disease (COPD) is the co-occurrence of chronic bronchitis and emphysema, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. This leads to a limitation of the flow of air to and from the lungs, causing shortness of breath (dyspnea). In contrast to asthma, this limitation is poorly reversible and usually gets progressively worse over time.